XTANDI (enzalutamide)
TherapyAstellas Pharma, Pfizer
Approvals
0
Indications
0
Biomarkers
0
Mapped tests
0
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and XTANDI. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where XTANDI is tied to a specific indication and biomarker definition.
No indication-specific companion diagnostic approvals are currently mapped for this therapy.
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for XTANDI.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering XTANDI for eligible patients.